News

WID®-easy test on ORF: ‘Bewusst Gesund’

WID®-easy test on ORF: ‘Bewusst Gesund’

On February 1, 2025, the WID®-easy test was presented in the ORF program “Bewusst Gesund”. The report shows how this innovative epigenetic test is revolutionizing the early detection of uterine cancer and can spare affected women invasive procedures.

IVD UKCA-marking for the WID®-easy test

IVD UKCA-marking for the WID®-easy test

The WID®-easy PCR Test Kit has received marketing authorization for the UK through registration of the IVD with the Medicines and Healthcare products Regulatory Agency (MHRA) and confirmation that the WID®-easy PCR Kit, manufactured by Sola Diagnostics GmbH, meets all applicable regulatory requirements under the UK Medical Devices Regulations 2002 (SI 2002 No. 618, as amended) (UK MDR 2002).

Interview with Silvia Gamper

Interview with Silvia Gamper

Silvia Gamper’s experience with postmenopausal bleeding highlights the importance of accessible, less burdensome healthcare solutions for women.

Frauenheilkunde Aktuell: Interview with Prof. Widschwendter on the WID®-easy Test

Frauenheilkunde Aktuell: Interview with Prof. Widschwendter on the WID®-easy Test

In the latest issue of Frauenheilkunde Aktuell, the biannual magazine of the SGGG (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe; en., Swiss Society of Gynecology and Obstetrics), the society’s president, Professor Michael Mueller, discusses the innovative WID-easy Test with Professor Martin Widschwendter, Director of the Institute for Prevention and Screening (EUTOPS).

Data on cervical cancer test WID®-can published in Nature Medicine

Data on cervical cancer test WID®-can published in Nature Medicine

The WID®-can test is referred to in the scientific literature as the WID-qCIN test and is an epigenetic test for the detection and prediction of cervical cancer.

New data from the EUTOPS team, working with Prof. Joakim Dillner and his team from the Karolinska Institute, has been published in Nature Medicine.

Equivalence of different sampling methods

Equivalence of different sampling methods

The study investigated whether different sampling methods influence the validity of the WID®-easy test (“WID-qEC test” in the scientific literature)

High-throughput analytics for the WID®-easy test

High-throughput analytics for the WID®-easy test

Martin Widschwendter's research team has developed the non-invasive methylation-based diagnostic WID®-easy test for the early detection of endometrial cancer based on quantitative real-time PCR that can be implemented in diagnostic high-throughput laboratory...

90 % less surgical diagnostic procedures with the WID®-easy test

90 % less surgical diagnostic procedures with the WID®-easy test

A recent study published in T H E L A N C E T O n c o l o g y demonstrated the ability of the new WID®-easy test to render 90% of surgical diagnostic procedures, e.g., hysteroscopy and curettage, unnecessary in women with abnormal bleeding during or after menopause....

Cell Paper: Biomarkers of Aging

Cell Paper: Biomarkers of Aging

Sola Dx's shareholders, Chiara Herzog and Martin Widschwendter, are making a significant contribution to a new international concept in aging research. In doing so, the researchers are opening up new avenues for the prevention of age-related diseases.Link to the...

The WID®-easy test featured in MedPage Today and ASCO

The WID®-easy test featured in MedPage Today and ASCO

Summary Prof Martin Widschwendter, Dr Chiara Herzog and the Team at the European Translational Oncology Prevention & Screening Institute, University of Innsbruck, have developed a new epigenetic test called WID-qEC (brand name: WID®easy) that screens for...

Chiara Herzog honored with Ernst Brandl Award for WID®-easy test

Chiara Herzog honored with Ernst Brandl Award for WID®-easy test

Foundation board member and district governor Michael Brandl, Monika Brandl, Ernst Brandl's widow, award winner Chiara Herzog, Vice Provost of University Innsbruck, Gregor Weihs, and mayor of the city of Schwaz, Mayor Victoria Weber. Dr. Chiara Herzog, head of...

DNA Methylation in Primary and Secondary Cancer Prevention

DNA Methylation in Primary and Secondary Cancer Prevention

Topics covered are: Unmet needs in cancer prevention P4-medicine The rationale for utilizing DNA-methylation for cancer risk prediction The principle of epigenetic-based risk prediction in surrogate tissue Cell type specificity (epithelial cells vs immune cells)...

Rethinking Cancer Risk Prediction

Rethinking Cancer Risk Prediction

The limitations of Polygenic Risk Scores ("PRS") for cancer risk prediction highlight the need for alternative methods that offer higher discriminatory power, prioritize poor prognostic cancers and account for a range of risk factors. Epigenetic-based approaches, such...

Early Cancer Detection: WID®-Tests reveal disease and risk

Early Cancer Detection: WID®-Tests reveal disease and risk

Scientists led by Martin Widschwendter (EUTOPS Institute) are developing methods for the early detection of women-specific cancers. With the help of the WID®-tests, epigenetic methods can detect already existing diseases, e.g., endometrial cancer using the...

Real-life cohort and validation for cervical cancer

Real-life cohort and validation for cervical cancer

WID-qEC test was validated in a real-life hospital cohort of 304 women. In addition, a case-control study showed the superiority of the WID-qEC test in the detection of cervical carcinoma, especially endocervical carcinoma, compared to cytological examination.Abstract...